Cell culture system for synthesis of infectious hepatitis C virus
View Patent ↗The invention rates to a hepatitis C virus (HCV) cDNA-based culture system capable of synthesis of infectious HCV in cell culture and cell-to-cell spread of the virus. The invention also relates to a method of measuring the level of HCV infection in a hepatocyte cell. A method for identifying a modulator of HCV activity is also presented, and a method for modulating HCV activity. The invention provides a reliable system for both genetic analysis of the viral genome and for the development of novel antiviral strategies.
1. A culture system for generating infectious hepatitis C virus (HCV) comprising preparing a cell culture medium from a cell culture, the cell culture produced by transfecting a hepatocyte cell with a nucleic acid sequence encoding HCV and nucleic acid sequence encoding RNA polymerase under conditions suitable for transfecting the cell, wherein following transfection, the cell culture medium contains infectious HCV.
2. The culture system of claim 1 , further comprising exposing the cell culture medium to a non-transfected hepatocyte cell, wherein following exposure, infectious HCV is secreted from the non-transfected hepatocyte cell.
3. The culture system of claim 2 , wherein the non-transfected hepatocyte cell is co-cultured with the transfected cell.
4. The culture system of claim 1 or 2 , further comprising isolating the cell culture medium containing infectious HCV.
5. The culture system of claim 1 , wherein the nucleic acid sequence encoding HCV and the nucleic acid sequence encoding RNA polymerase are in a single plasmid.
6. The culture system of claim 1 , wherein the nucleic acid sequence encoding HCV is contained in a first plasmid and the nucleic acid sequence encoding RNA polymerase is in a second plasmid.
7. The culture system of claim 1 , wherein the transfecting comprises transfecting the hepatocyte cell with a nucleic acid sequence encoding NS3 and NS5B.
8. The culture system of claim 7 , wherein the nucleic acid sequence encoding HCV, the nucleic acid sequence encoding RNA polymerase and nucleic acid sequence encoding NS3 and NS5B are in a single plasmid.
9. The culture system of claim 7 , wherein nucleic acid sequence encoding HCV, the nucleic acid sequence encoding RNA polymerase and nucleic acid sequence encoding NS3 and NS5B are contained in more than one plasmid.
10. The culture system of claim 1 or 2 , wherein the hepatocyte cells are derived from human tissue.
11. The culture system of claim 10 , wherein the hepatocyte cells are hepatocellular carcinoma cells.
12. The culture system of claim 11 , wherein the cell is Huh-7, HepG2, C3A or PLC.
13. The culture system of claim 1 , wherein the HCV is type 1a HCV or type 1b HCV.
14. The culture system of claim 1 , wherein the RNA polymerase is a T7 RNA polymerase.
15. The culture system of claim 1 , wherein the nucleic acid sequence encoding HCV includes a promoter, wherein the promoter is activated by the RNA polymerase.
16. The culture system of claim 15 , wherein the promoter is T7, SP6 or QB.
17. A method for generating infectious hepatitis C virus (HCV) comprising preparing a cell culture medium from a cell culture, the cell culture produced by transfecting a hepatocyte cell with a nucleic acid sequence encoding HCV and nucleic acid sequence encoding RNA polymerase under conditions suitable for transfecting the cell, wherein following transfection, the cell culture medium contains infectious HCV.
18. The method of claim 17 , further comprising exposing the cell culture medium to a non-transfected hepatocyte cell, wherein following exposure, infectious HCV is secreted from the non-transfected hepatocyte cell.
19. The method of claim 18 , wherein the non-transfected hepatocyte cell is co-cultured with the transfected cell.
20. The method of claim 17 or 18 , further comprising isolating the cell culture medium containing infectious HCV.
21. The method of claim 17 , wherein the nucleic acid sequence encoding HCV and the nucleic acid sequence encoding RNA polymerase are in a single plasmid.
22. The method of claim 17 , wherein the nucleic acid sequence encoding HCV is contained in a first plasmid and the nucleic acid sequence encoding RNA polymerase is in a second plasmid.
23. The method of claim 17 , wherein the transfecting comprises transfecting the hepatocyte cell with a nucleic acid sequence encoding NS3 and NS5B.
24. The method of claim 23 , wherein the nucleic acid sequence encoding HCV, the nucleic acid sequence encoding RNA polymerase and nucleic acid sequence encoding NS3 and NS5B are in a single plasmid.
25. The method of claim 23 , wherein nucleic acid sequence encoding HCV, the nucleic acid sequence encoding RNA polymerase and nucleic acid sequence encoding NS3 and NS5B are contained in more than one plasmid.
26. The method of claim 17 or 18 , wherein the hepatocyte cells are derived from human tissue.
27. The method of claim 26 , wherein the hepatocyte cells are hepatocellular carcinoma cells.
28. The method of claim 27 , wherein the cell is Huh-7, HepG2, C3A or PLC.
29. The method of claim 17 , wherein the HCV is type 1a HCV or type 1b HCV.
30. The method of claim 17 , wherein the RNA polymerase is a T7 RNA polymerase.
31. The method of claim 17 , wherein the nucleic acid sequence encoding HCV includes a promoter, wherein the promoter is activated by the RNA polymerase.
32. The method of claim 31 , wherein the promoter is T7, SP6 or QB.